Cardiac Risks and Management of Moderate Hypokalemia (Serum K⁺ ≈ 2.9 mEq/L)

1. Arrhythmogenic Potential of Moderate Hypokalemia

Moderate hypokalemia (serum potassium 2.5–2.9 mEq/L) markedly increases the risk of life‑threatening ventricular arrhythmias and therefore warrants urgent correction. 1

The American Heart Association notes that potassium levels around 2.9 mEq/L commonly produce ST‑segment depression, flattened or broadened T waves, and prominent U waves—electrocardiographic markers of heightened electrical instability. 2

Patients with structural heart disease (e.g., heart failure, coronary artery disease, left‑ventricular hypertrophy), acute myocardial infarction, or those receiving digitalis therapy experience a substantially amplified arrhythmia risk at this potassium concentration. 1
Concomitant use of QT‑prolonging medications (antiarrhythmics, certain antibiotics, antipsychotics) further elevates the danger. 1
Rapid declines in serum potassium, as opposed to chronic stable low levels, are associated with a higher propensity for ventricular ectopy. 1
Co‑existing hypomagnesemia—present in roughly 40 % of hypokalemic individuals—independently predisposes to arrhythmias and must be addressed first. 1

Obtain a 12‑lead ECG within the first 15 minutes to identify the ECG changes described above. 1
Simultaneously measure serum magnesium; target a magnesium level above the lower normal limit before initiating potassium repletion. 1

In patients with cardiac risk factors, aim for a serum potassium of 4.0–5.0 mEq/L rather than merely exceeding 3.5 mEq/L. 1
Initiate intravenous potassium chloride at 20–30 mEq diluted in 1 L of isotonic fluid, limiting the peripheral infusion rate to ≤10 mEq/h (≤20 mEq/h via central line) while monitoring cardiac rhythm. 1
When oral therapy is appropriate (low‑risk patients), administer 40–60 mEq of potassium per day divided into 2–3 doses, with repeat potassium measurement in 24–48 hours. 1

Correcting magnesium deficiency before potassium supplementation is the single most effective maneuver to overcome refractory hypokalemia. 1

The 2010 International Consensus on Cardiopulmonary Resuscitation (American Heart Association) states that the benefit of rapid bolus potassium during cardiac arrest is uncertain and generally advises against its routine use. 3
Nevertheless, if hypokalemia is identified early as the reversible cause of arrest, targeted intravenous potassium may be administered after magnesium correction, balancing the potential for rapid reversal against the paucity of high‑quality evidence. 3

Do not administer potassium without first ensuring adequate magnesium levels, as magnesium deficiency impairs potassium transport and promotes renal potassium loss. 1
Avoid aggressive potassium repletion in patients concurrently receiving ACE inhibitors or ARBs without close electrolyte monitoring, to prevent rebound hyperkalemia. 1
Discontinue or reduce potassium‑wasting diuretics when serum potassium falls below 3.0 mEq/L; consider adding a potassium‑sparing diuretic for persistent losses. 1
Refrain from NSAID use during active potassium replacement, as these agents can worsen renal function and precipitate dangerous electrolyte shifts. 1